Welcome to our dedicated page for IGC Pharma SEC filings (Ticker: IGC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IGC Pharma, Inc. (NYSE American: IGC) SEC filings page on Stock Titan aggregates the company’s official disclosures to the U.S. Securities and Exchange Commission, providing a structured view of its regulatory and corporate history. As a Maryland-incorporated, clinical-stage biotechnology company focused on Alzheimer's disease, pharmaceutical cannabinoids, and AI-driven research, IGC Pharma uses SEC filings to report material events, capital transactions, governance actions, and financial reporting changes.
Investors reviewing IGC Pharma’s filings will find multiple Form 8-K current reports detailing key developments. Recent 8-Ks describe a registered direct offering under an effective Form S-3 shelf registration statement, including a Subscription Agreement for the sale of common stock and the intended use of proceeds for working capital and clinical development programs. Other 8-Ks outline the completion of a Sale of Assets and Manufacturing Agreement through the company’s Holi Hemp LLC subsidiary, documenting the disposition of certain equipment, inventory, and operating assets of a Vancouver, Washington facility and the associated preferential supply rights and contingent consideration.
Additional 8-K filings and the DEF 14A proxy statement provide information on corporate governance and capital structure. These documents cover stockholder approval to increase authorized common stock from 150,000,000 to 600,000,000 shares, amendments to the Articles of Incorporation to implement that increase, and the election of directors and ratification of the independent registered public accounting firm. Another 8-K reports a change in fiscal year-end from March 31 to December 31 and the plan to file a transition report on Form 10-K for the nine-month period from April 1, 2025, through December 31, 2025.
Through Stock Titan, users can access IGC Pharma’s 10-K, 10-Q, 8-K, and proxy materials as they appear on EDGAR, along with AI-powered summaries that highlight the main points of lengthy documents. These summaries help explain complex topics such as equity offerings under a shelf registration, asset sale terms, changes in authorized share capital, or fiscal year transitions. The filings page is also the place to monitor exhibits such as material contracts, legal opinions, and pro forma financial information referenced in 8-Ks.
For those tracking IGC Pharma’s stock, this page offers a way to review how the company reports on its clinical-stage operations, capital planning, governance decisions, and other material events through official SEC channels, with AI tools available to make dense regulatory text more accessible.
IGC Pharma (NYSE:IGC) filed its Form 10-K for the fiscal year ended March 31 2025. The company remains a non-accelerated, smaller reporting company with 83.9 million common shares outstanding and an aggregate non-affiliate market value of $29.7 million as of Sept 30 2024.
Management reiterates its mission to advance IGC-AD1—now in Phase 2 clinical trials for Alzheimer’s agitation—while investing in an AI-driven early-diagnosis platform. The filing lists extensive risk factors covering cash sufficiency, regulatory approvals, IP protection, clinical-trial funding, and cybersecurity. No restatements, auditor ICFR attestation, or material acquisitions/dispositions were disclosed. Standard sections (MD&A, financials, controls) are included, and the company confirms timely SEC compliance.